Medical Devices; Cardiovascular Devices; Classification of the Cardiovascular Machine Learning-Based Notification Software
Key claim: The FDA is placing cardiovascular machine-learning software that sends health notifications into the moderate-risk class II device category with special controls, which it says will keep the products reasonably safe while making them easier to bring to patients.
Abstract
(Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is classifying the cardiovascular machine learning-based notification software into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the cardiovascular machine learning- based notification software. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients’ access to beneficial innovative devices, in part by reducing regulatory burdens.
Why this matters
FDA is building out AI/ML device governance one product category at a time rather than through a single horizontal AI-device rule, and this cardiovascular notification classification is a concrete second data point in that pattern after the radiology ML imaging rule. For developers of clinical AI, the direction is toward Class II special-controls pathways with device-specific performance and labeling expectations, which is faster to market than de novo or PMA but locks in agency-set constraints on how the software behaves and communicates risk.